Compare
HeartBeam, Inc. vs Biotricity Inc. vs Medinotec Inc. vs Bluejay Diagnostics, Inc.
| Latest fiscal year | HeartBeam, Inc. BEAT | Biotricity Inc. BTCY | Medinotec Inc. MDNC | Bluejay Diagnostics, Inc. BJDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2026-02-28 | 2025-12-31 |
| Revenue | n/a | $16.00M | $9.73M | n/a |
| Revenue growth (YoY) | n/a | +16.0% | +6.8% | n/a |
| Gross margin | n/a | 80.9% | 52.7% | n/a |
| Operating margin | n/a | 10.6% | 11.2% | n/a |
| Net margin | n/a | -15.0% | 8.2% | n/a |
| Net income | -$21.02M | -$2.40M | $794.5K | -$6.85M |
| EPS (Diluted) | -$0.62 | -$0.12 | n/a | -$15.25 |
| Operating cash flow | -$13.99M | -$719.0K | $906.8K | -$6.05M |
| Free cash flow | -$14.59M | n/a | $905.4K | -$6.23M |
| Cash & equivalents | $4.38M | $149.8K | n/a | $5.16M |
| Total assets | $5.84M | $6.45M | $6.81M | $7.12M |
| Total liabilities | $3.24M | $39.41M | $1.10M | $1.14M |
| Shareholders' equity | $2.60M | -$34.68M | $5.71M | $5.98M |
| Return on year-end equity | -807.3% | n/a | 13.9% | -114.6% |
| Shares outstanding | 26.96M | 28.60M | 11.76M | 604.5K |
Revenue, most recent five fiscal years
| Fiscal year | HeartBeam, Inc. | Biotricity Inc. | Medinotec Inc. | Bluejay Diagnostics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $16.00M Ended 2026-03-31 | $9.73M Ended 2026-02-28 | $249.0K Ended 2022-12-31 |
| 1 year earlier | n/a | $13.79M Ended 2025-03-31 | $9.11M Ended 2025-02-28 | n/a |
| 2 years earlier | n/a | $12.06M Ended 2024-03-31 | $5.02M Ended 2024-02-29 | n/a |
| 3 years earlier | n/a | $9.64M Ended 2023-03-31 | $999.6K Ended 2023-02-28 | n/a |
| 4 years earlier | n/a | $7.65M Ended 2022-03-31 | n/a | n/a |